Overcoming challenging targets in antibody discovery
Webinar Overview: Unlock solutions for your most challenging targets with this webinar that demonstrates how Alloy Therapeutic’s precision approach to antibody discovery delivers results. This technical discussion explores: The power of hyperimmune mice: Benefit from ATX-GKH’s enhanced immune responses that produce higher serum titers and increased lymphoid cell output, especially valuable for high homology Streamline […]
Identify functional chimeric antigen receptors three months faster with Alloy’s end-to-end CAR discovery
Webinar overview: Looking for a way to accelerate your CAR-T therapeutic development projects? This presentation highlights how Alloy’s comprehensive platform and expertise can enable you to: Streamline end-to-end CAR discovery: Learn how Alloy’s full stack technologies enable discovery and screening of functional CARs with unprecedented speed and cost efficiency, overcoming limitations of conventional two-step processes. […]
Discover TCR mimic antibodies that Target Previously “Undruggable” Intracellular Proteins with Keyway™ TCR
Webinar Overview: Unlock access to intracellular protein targets and maximize TCRm/TCR-based therapeutic antibody discovery with this presentation by Dr. Dongxing Zha that reveals how Alloy’s proprietary Keyway™ TCRm Discovery Platform and expertise can: Overcome challenges to intracellular protein-targeted drug discovery: Learn how the Keyway™ TCRm Discovery Platform identifies TCR mimic (TCRm) antibodies that target intracellular […]
Accelerating Bispecific Discovery with the Alloy Common Light Chain Platform
Webinar Overview Discover the full potential of bispecific antibody therapeutics and how to accelerate their discovery during this presentation by Dr. Lucy Liu that reveals how Alloy’s technologies, services, and expertise is able to: Accelerate bispecific antibody discovery: Learn how the Alloy Common Light Chain (CLC) human, transgenic platform streamlines bispecific antibody discovery and development, […]
Accelerating Therapeutic Discovery: ATX-Gx™ Human, Transgenic Platform
Webinar Overview Ready to dramatically accelerate your therapeutic antibody discovery pipeline? In this presentation, Dr. John “Lippy” Lippincott shares how our ATX-Gx™ human, transgenic mouse platform can help: Accelerate antibody discovery: Learn how this platform, used by 100’s of biotechs and large pharma, can significantly speed up the identification of therapeutic antibody candidates against diverse […]
Alloy Therapeutics Announces Institutional License Agreement with Scripps Research for its ATX-Gx™ Platform for Fully Human Antibody Discovery
— Agreement provides Scripps Research scientists with broad access to Alloy’s fully human transgenic mouse platform, which has the power to increase the pace and success rate of antibody discovery and vaccine development efforts. — BOSTON, Mass., October 30th, 2024 – Alloy Therapeutics, a biotechnology ecosystem company dedicated to democratizing access to biologics drug discovery platforms […]
Alloy Therapeutics Announces Platform License Agreement with Lilly
BOSTON, Mass., May 21st, 2024 – Alloy Therapeutics, a biotechnology ecosystem company dedicated to democratizing access to biologics drug discovery platforms and services, announced today a licensing agreement for its murine platforms for fully human antibody discovery with Eli Lilly and Company. The non-exclusive license provides Lilly access to the ATX-Gx™ and ATX-CLC™ mouse platforms […]
Alloy Therapeutics Expands Executive Team to Strengthen Therapeutic Discovery and Innovation for Its Partners
Biotherapeutic discovery and development expert Michael Schmidt joins as CSO to manage an expansive roadmap of technical innovation across Alloy’s platforms, services, and company formation in six modalities. Alloy’s Martin Leach is promoted to COO to expand the company’s operational excellence and discovery services capacity for partners. BOSTON, Mass. – June 28, 2023 — Alloy Therapeutics, […]
Alloy Therapeutics Announces an Expansion of its Antibody Discovery Services in Conjunction with Two New Senior Vice Presidents
Alloy Antibody Discovery Services offers partners a modular campaign design that can meet their goals and budgets as they collaborate to discover the best antibodies with therapeutic potential. BOSTON, Mass. – April 26, 2023 — Alloy Therapeutics, a biotechnology ecosystem company, announced the appointment of Kent Bondensgaard and John “Lippy” Lippincott as the latest members […]
Alloy Therapeutics Raises $42 Million Series D Financing to Accelerate Discovery Technology Development Across Biologic Modalities
— Following a successful expansion from antibodies into T-cell receptors and genetic medicines, Alloy will broaden its pre-competitive discovery technology and discovery services to enable innovative new therapeutic formats — BOSTON, MA; October 03, 2022—Alloy Therapeutics, a biotechnology ecosystem company, has closed $42 million in Series D financing led by its existing investors 8VC and Mubadala […]